|United States Of America||Published Application||20210340199||11/04/2021||2019-008|
|United States Of America||Published Application||20210095004||04/01/2021||2019-008|
|Patent Cooperation Treaty||Published Application||WO2020055748||03/19/2020||2019-008|
Additional Patents Pending
Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9 nucleases, when complexed with a guide RNA, effect genome editing in a sequence-specific manner. RNA-guided Cas9 has proven to be a versatile tool for genome engineering in multiple cell types and organisms. There is a need in the art for additional compositions and methods for controlling genome editing activity of CRISPR/Cas9.
UC Berkeley researchers have discovered a new protein that is able to inhibit the Cas9 protein from
Staphyloccocus aureus (SauCas9). SauCas9 is smaller than the frequently used Cas9 from Streptococcus pyogenes, which has a number of benefits for delivery. The inhibitor is a small protein from a phage and is capable of strongly inhibiting gene editing in human cells.